New drug may better treat strand of staph infections
Doctors might soon have a new option for treating methicillin-resistant Staphylococcus aureus, or MRSA. Researchers at Paratek Pharmaceuticals, a Boston-based company, announced Oct. 26 that Phase II testing of the drug PTK 0796 yielded positive results.